What's in Mountain Diabetes and Endocrine Center's pipeline?

Mountain Diabetes and Endocrine Center has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Mountain Diabetes and Endocrine Center's portfolio?

Top competitors by shared drug class: Boston Medical Center, Eli Lilly and Company, Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud, Geropharm, Jesús Moreno Fernández.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mountain-diabetes-and-endocrine-center.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Mountain Diabetes and Endocrine Center — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mountain Diabetes and Endocrine Center pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Faster Insulin Aspart (Fiasp®)	Faster Insulin Aspart (Fiasp®)	marketed	Rapid-acting insulin analog	Insulin receptor	Diabetes

Therapeutic area mix

Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Boston Medical Center · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · 1 shared drug class
Geropharm · 1 shared drug class
Jesús Moreno Fernández · 1 shared drug class
Mylan Inc. · 1 shared drug class
Nanjing First Hospital, Nanjing Medical University · 1 shared drug class
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mountain Diabetes and Endocrine Center:

Cite this brief

Drug Landscape (2026). Mountain Diabetes and Endocrine Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mountain-diabetes-and-endocrine-center. Accessed 2026-05-17.